Search

Diffuse intrinsic pontine glioma (DIPG) poses a significant treatment challenge in pediatric patients due to its aggressive nature and difficulty in crossing the blood-brain barrier with effective therapies. ONC201 (dordaviprone) shows promises in inducing apoptosis in cancer cells but suffers from poor water solubility and stability issues. Moreover, conventional solubilizing agents acceptable in formulations intended for adult patients are not suitable for pediatric use. So, this study aims to develop a stable, concentrated oral solution of ONC201 suitable for pediatric dosing without harmful excipients and efficient taste masking. Based on Molecular Dynamics simulations, a first screening among a selection of hydrotropes was carried out and, from the results obtained, nicotinamide was selected for experimental study. Given ONC201's challenges of poor solubility and stability, the formulation's physical and chemical properties were meticulously optimized. Extensive analyses, including differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), powder X-ray diffraction (PXRD), and nuclear magnetic resonance (NMR) spectroscopy, confirmed the solution's stability across various storage conditions, with no evidence of precipitation or significant degradation. This newly formulated solution is now used inside daily practice in the French compassionate Use Program to give access to ONC201 allowing treating patients who suffer from swallowing disorders., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)

A major issue of the pharmaceutical industry is the poor solubility, permeability, and bioavailability of most active ingredients. These properties also induce the accumulation of pharmaceuticals in groundwater, surface water, wastewater, soils and biota. Therefore, enhancing the solubility and bioavailability of pharmaceuticals could allow the prescription of lower doses, and could reduce environmental impact. Pharmaceutical solubility can be increased by pH modification, salt formation, ionization, complexation, and co-solvency. Here we report for the first time the use of cyclodextrin-based low-melting mixtures for the solubilization of four steroids: beclomethasone dipropionate, budesonide, fluticasone propionate and mometasone furoate. First, a low-melting mixture was prepared from sulfobutylether-β-cyclodextrin and levulinic acid, and characterized. Then, the shake flask method was used to determine the solubility of the drugs in this low-melting mixture. Results show a 4000-fold increase of the solubility of fluticasone propionate using the low-melting, cyclodextrin-based mixture versus water. This huge solubility enhancement could be explained by the formation of an inclusion complex with the cyclodextrin within the low-melting mixture. [ABSTRACT FROM AUTHOR]

Four new cucurbiturils Cy nCB[6] containing n ( n = 1, 2, 4, 5) cyclohexyl equatorial units have been synthesized to complete the family of known Cy3CB[6] and Cy6CB[6] derivatives. A new CB[6] member bearing a propanediurea unit has also been prepared. The CB[6] derivatives show better solubility in pure water than native CB[6]. One cyclohexyl unit is sufficient to enhance the solubility in water by a factor of 170 with respect to CB[6], and Cy6CB[6] is around 30 times more soluble than Cy1CB[6]. The cyclohexane moieties, by limiting or impeding the formation of intermolecular C-H ···O hydrogen bonds, may explain this increase in solubility. The effect of modification of the molecular shape on the solubility was assessed by liquid-state NMR spectroscopy and DFT calculations. [ABSTRACT FROM AUTHOR]